Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Dinaciclib in R/R AML
NCT03484520Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Jul 2018
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of dinaciclib in acute myeloid leukemia (AML), sponsored by AbbVie Inc. Primary endpoints: Time to Maximum Plasma Concentration (Tmax) of Venetoclax at Day 29, Recommended Phase 2 Dose (RPTD) at 21 days and 8 more. Started Jul 2018; status: terminated.
02
Drugs
dinaciclib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03484520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03484520.